Abstract

While a wealth of literature for tissue-specific liposomes is emerging, optimal formulations to target the cells of the peripheral nervous system (PNS) are lacking. In this study, we asked whether a novel formulation of phospholipid-based liposomes could be optimized for preferential uptake by microvascular endothelia, peripheral neurons and Schwann cells. Here, we report a unique formulation consisting of a phospholipid, a polymer surfactant and cholesterol that result in enhanced uptake by targeted cells. Using fluorescently labeled liposomes, we followed particle internalization and trafficking through a distinct route from dextran and escape from degradative compartments, such as lysosomes. In cultures of non-myelinating Schwann cells, liposomes associate with the lipid raft marker Cholera toxin, and their internalization is inhibited by disruption of lipid rafts or actin polymerization. In contrast, pharmacological inhibition of clathrin-mediated endocytosis does not significantly impact liposome entry. To evaluate the efficacy of liposome targeting in tissues, we utilized myelinating explant cultures of dorsal root ganglia and isolated diaphragm preparations, both of which contain peripheral neurons and myelinating Schwann cells. In these models, we detected preferential liposome uptake into neurons and glial cells in comparison to surrounding muscle tissue. Furthermore, in vivo liposome administration by intramuscular or intravenous injection confirmed that the particles were delivered to myelinated peripheral nerves. Within the CNS, we detected the liposomes in choroid epithelium, but not in myelinated white matter regions or in brain parenchyma. The described nanoparticles represent a novel neurophilic delivery vehicle for targeting small therapeutic compounds, biological molecules, or imaging reagents into peripheral neurons and Schwann cells, and provide a major advancement toward developing effective therapies for peripheral neuropathies.

Highlights

  • Targeted delivery of therapeutic compounds to specific cell types is critical in developing effective and safe treatments for neurodegenerative disorders

  • Using in vitro and in vivo model systems, here we demonstrate that our novel liposome formulation composed of DOPC/Poloxamer 188 (P188)/ Chol is avidly taken up by microvascular endothelia, choroid epithelia, peripheral neurons, and myelinating and non-myelinating Schwann cells

  • The addition of P188 modestly increased liposome uptake by all neural cells compared to DOPC alone, while the addition of Chol enhanced uptake by 5, 11- and 8-fold for Schwann cells, SH-SY5Ys and Brain microvascular endothelial cells (BMECs), respectively

Read more

Summary

Introduction

Targeted delivery of therapeutic compounds to specific cell types is critical in developing effective and safe treatments for neurodegenerative disorders. This challenge is great when designing reagents for diseases of the peripheral nervous system (PNS), such as hereditary motor and sensory neuropathies (HMSNs). As liposomes are known to enter cells primarily via the endocytic pathway [1,2], and endocytosis is central for neuronal activity [3,4,5], we chose liposomes for further development. While the role of endocytosis in Schwann cells is less understood, recent studies demonstrate the involvement of the endocytic pathway in membrane remodeling during myelination [6,7]. Remyelination of regenerated peripheral nerves is dependent on an intact endosomal-lysosomal system [8]

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.